Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
The 509F6 monoclonal antibody specifically binds to Fc receptor-like 5 (FCLR5), a type I transmembrane glycoprotein that is also known as CD307e, FCRH5 (Fc receptor homolog 5) and IRTA2 (immunoglobulin superfamily receptor translocation associated 2). FCRL5 (CD307e) is a member of the Immunoglobulin (Ig) gene superfamily with 9 extracellular Ig domains, an intracellular immunoreceptor tyrosine-based activating motif (ITAM)-like sequence and two intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM)-like sequences. Like other Fc receptor-like proteins, FCRL5 (CD307e) is homologous to FcγR1 (CD64) and binds to immunoglobulins, specifically the IgG isotypes, and it may play a role in the regulatory interactions of immune complexes with B lymphocytes. FCRL5 (CD307e) is differentially expressed in the B cell lineage, with little expression on peripheral blood cells and upregulated expression on plasma cells and some leukemias and lymphomas. mAb 509F6 binds to an epitope within the first 3 Ig domains of FCRL5 and blocks FCRL5's interaction with immune complexes.
The antibody was conjugated to BD Horizon BV480 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 436-nm and Em Max at 478-nm, BD Horizon BV480 can be excited by the violet laser and detected in the BD Horizon BV510 (525/40-nm) filter set. BV480 has less spillover into the BV605 detector and, in general, is brighter than BV510.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.